High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*
By R. Shields, Angela K. Namenuk, Kyu Hong, Y. Meng, J. Rae, J. Briggs, Dong Xie, Jadine Lai, A. Stadlen, Betty Li and 2 more. 2001
1,075 citations recorded by the source corpus.
Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated immune responses with cellular effector functions. A high resolution map of the binding site on human IgG1 for human FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, and FcRn receptors has been determined. A common set of IgG1 residues is involved in binding to all FcγR; FcγRII and FcγRIII also utilize residues outside this common set. In addition to residues which, when altered, abrogated binding to one or more of the receptors, several residues were found that improved binding only to specific receptors or simultaneously improved binding to one type of receptor and reduced binding to another type. Select IgG1 variants with improved binding to FcγRIIIA exhibited up to 100% enhancement in antibody-dependent cell cytotoxicity using human effector cells; these variants included changes at residues not found at the binding interface in the IgG/FcγRIIIA co-crystal structure (Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000)Nature 406, 267–273). These engineered antibodies may have important implications for improving antibody therapeutic efficacy.
Subfields: Molecular Biology, Radiology, Nuclear Medicine and Imaging
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- G. Vidarsson
- G. Dekkers
- T. Rispens
Citations in the corpus
- Therapeutic antibodies: successes, limitations and hopes for the future (2009, neutral): “…to increase the efficiency of therapeutic antibodies would be to increase their binding to activating receptors, namely FcgRI, FcgRIIa and more importantly FcgRIIIa, and decrease their interaction with inhibitory FcgRIIb receptors (Shields et al., 2001; Lazar et al., 2006; Desjarlais et al., 2007).”
- IgG Subclasses and Allotypes: From Structure to Effector Functions (2014, background): “Besides changing amino acids 233–236 from IgG1 to the IgG2 equivalents, A327G (Ala present in IgG1 and IgG3, Gly in IgG2 and IgG4) also results in decreased binding (151).”